Low operational predictability
Recurring failures, blind spots on critical assets and weak life-cycle view at the exact moment production must stabilise.
GMP pharma capital projects · AI-enabled delivery
Reliability. Before the plant starts.
ReliaPharma engineers maintenance, asset data, spare-parts strategy, CMMS readiness and reliability routines into new GMP pharma facilities before FAT, SAT and handover — accelerated by AI, validated by senior GMP reliability engineers.
100%Focused on GMP pharma pre-startup work
4Step delivery method built for capital projects
7Phase framework for Initial Asset Control
Initial Asset Control Dossier
Start-up readiness, engineered into the project.
Phase gate ready
DesignReliability requirements defined
BuildAsset data and PM logic created
FAT / SATHandover evidence controlled
Day 1O&M routines live in CMMS
Commissioning handover pack
What must exist before the first batch.
1Functional locationsISO
2Criticality and FMEARBM
3PM / CM job plansGxP
4Critical spares policyDay 1
Controlled outputs
Asset structure, risk logic, job plans and critical spares aligned before handover.
Readiness profile
Evidence status across start-up and audit-readiness records.
GMPControlled evidence
Data, risk logic, PM plans, critical spares and gate evidence are reviewed as one readiness system.
AI-assisted. Engineer-validated. Audit-aware.Fixed-scope engineering deliverables for GMP pharma projects.
Capital project reality
Reliability gaps become start-up gaps.
In new GMP facilities, reliability failure is rarely a single technical event. It is usually a missing system: asset hierarchy, criticality, PM logic, spares, handover evidence, training and governance were not designed as one program.
Reactive maintenance cost
Corrective work, mis-prioritised backlog and budgets built on history rather than risk, criticality and real workload.
Thin handover maturity
Technical decisions, CMMS data, operating routines and acceptance criteria remain undocumented or unready for audit.
Fragmented ownership
Project, maintenance, operations, quality, supply chain and finance optimise locally while no one owns the integrated system.
AI solutions
AI-enabled delivery for GMP reliability work.
ReliaPharma concentrates AI on the technical work of phases 3–5: structuring asset data, processing technical documentation and accelerating FMEA/PM content. The readiness cockpit can consolidate approved records for visibility, but governance, phase-gate decisions, commissioning acceptance and stabilisation remain engineer-led and grounded in pharma GMP practice. Every controlled output is reviewed before client release.
Turn the project data room into a usable asset baseline.
AI helps read high-volume documentation and propose structured asset records. ReliaPharma engineers then check the logic, resolve exceptions and prepare client-ready registers.
- Equipment list normalization, functional-location candidates and ISO 14224-style hierarchy checks.
- OEM manual extraction for maintainable items, spare-parts clues and inspection requirements.
- Gap logs showing missing tags, missing documentation, inconsistent names and incomplete handover evidence.
Draft faster, then validate like a regulated engineering deliverable.
AI accelerates first-pass FMEA and PM/CM work-instruction drafts. The final logic is reviewed by senior reliability engineers against criticality, OEM guidance, GxP impact and site standards.
- Failure-mode libraries mapped to equipment classes and operating context.
- PM, PdM and operator-round task drafts with frequencies, tools, precautions and acceptance criteria.
- Reviewer comments, assumption logs and traceability back to source documents.
Find CMMS defects before they become day-one maintenance defects.
AI-assisted checks expose master-data inconsistencies early enough to correct them before loading the CMMS or before using it as the maintenance record of evidence.
- Missing field, duplicate asset, naming-standard and taxonomy conformance checks.
- PM plan completeness checks against criticality, equipment class and GxP impact.
- Upload templates, exception reports and controlled remediation lists for project teams.
Make readiness visible before the project reaches the gate.
AI helps compile recurring readiness and stabilization reporting from structured inputs, so leaders see gate risk, open actions and maintenance readiness without rebuilding the same spreadsheet every week.
- ORA evidence status, punch-list risk and phase-gate exception reporting.
- Readiness dashboard for asset data, PM plans, spares, training and commissioning records.
- Monthly stabilization summaries covering failures, PM compliance, spares and plan adjustments.
CMMS readiness exceptions
Controlled release
No black-box deliverables.
Every AI-assisted output carries source references, assumptions, review status and owner sign-off before client release.
Source linked
Engineer reviewed
Owner approved
0Unreviewed outputs sent as final engineering deliverables.
NDAClient data isolated; deployment model scoped with IT and quality.
GxPTraceable outputs designed for regulated maintenance workflows.
How we engage
A four-step method built for capital projects.
The method turns project documentation into operating capability: asset data, maintenance logic, execution processes and internal competence.
Asset Data & Maintenance Strategy
Build the reliability baseline before the plant becomes operational.
- Data evaluation
- Equipment hierarchy
- Criticality assessment
- FMEA on critical assets
Maintenance Execution Excellence
Define how work will be performed, recorded and governed.
- CM and PM work instructions
- Technical competence matrix
- Staffing and budgeting strategy
- GxP traceability
Reliability Engineering Processes
Create the routines that prevent recurring failures after start-up.
- RBM framework live
- FRACAS and RCA
- Preventive Maintenance Optimisation
- Loss elimination routines
Education, Training & Coaching
Give teams the capability to sustain the system after the project team leaves.
- RBM training
- RCM/FMEA training
- RCA training
- 1-on-1 coaching
Initial Asset Control
Seven phases from governance to hypercare.
Initial Asset Control is one phase-gated operating model. Planning and project requirements define the rules; phases 3–5 build the maintainable asset baseline; commissioning verifies evidence and formal handover; hypercare stabilises performance. AI is applied selectively only where it materially improves technical delivery—master data, technical documentation and O&M preparation.
Define and govern
Establish scope, RACI, project requirements, acceptance criteria and risk controls.
Build the technical baselineSelective AI support
Structure asset data, control technical information and prepare maintenance execution.
Verify and stabilise
Confirm readiness, formalise handover and stabilise the operating system.
1Governance control
Planning & Governance
Establish the governance system that keeps scope, decisions, risks and phase-gate acceptance under control.
Pharma governance: accountable decisions, phase gates and risk controls.
- Charter, scope and integrated schedule
- RACI, governance rituals and decision rights
- Phase gates, acceptance criteria and risk plan
2Requirements baseline
Project Requirements
Translate operability, maintainability, integration and reliability expectations into explicit project requirements.
Best-practice requirements: operability, maintainability, integration and reliability.
- Asset and system-integration requirements
- Operability and maintainability criteria
- Criticality, reliability and gap treatment
3AI-assisted
Master Data & Structuring
Create the controlled asset structure required by CMMS/EAM, maintenance strategy and lifecycle reporting.
Asset-data extraction and quality control
- System breakdown and ISO 14224 hierarchy
- TAG, functional-location and master-data standards
- BOM rules, data-load logic and quality checks
4AI-assisted
Technical Documentation
Consolidate the technical baseline and preserve the document trail needed for controlled handover and future maintenance.
Document intelligence and traceability
- Technical baseline and master document register
- As-builts, technical dossier and O&M manuals
- Change control and source traceability before handover
5AI-assisted
O&M Preparation
Convert the asset baseline into executable O&M routines, maintenance plans, spares and competent resources.
FMEA and PM draft acceleration
- SOPs, FMEA/RCM and maintenance strategy
- PM/CM job plans and critical-spares provisioning
- Competence, training and Day-1 execution readiness
6Commissioning assurance
Commissioning
Verify that records, certificates, punch items and ORA evidence support a formal, controlled handover.
Commissioning assurance: ORA, evidence completeness and formal acceptance.
- Commissioning records and test certificates
- Punch-list classification and ORA verification
- Formal handover package and accountable acceptance
7Stabilisation control
Hypercare
Stabilise performance after handover, close early-life gaps and convert lessons learned into sustained operating routines.
Stabilisation discipline: KPI review, early-life issue closure and controlled learning.
- Post-handover monitoring and stabilisation report
- KPI review and O&M plan adjustments
- Early-life issue closure, lessons learned and benefits
Selective AI, not blanket automation.
AI supports phases 3–5 to accelerate data structuring, document processing and maintenance-content drafting. Phases 1, 2, 6 and 7 remain led by established pharma GMP, ISPE, project-governance, commissioning and stabilisation practices.
Standards and frameworks
Every deliverable references a recognised body of practice.
ReliaPharma work is positioned for regulated environments: traceable, reviewable, phase-gated and ready for quality, operations and maintenance stakeholders.
Maintenance Good Practice
Maintenance program, roles, data, PMO, KPIs and lifecycle alignment.
ISO 14224
Equipment hierarchy, functional locations and reliability data taxonomy.
JA1011 / JA1012
Reliability-Centred Maintenance criteria and FMEA discipline.
ICH Q9
Quality risk identification, analysis, evaluation, control, communication and review.
21 CFR Part 11
Electronic records, signatures, audit trails and data integrity implications.
GAMP 5
CMMS/EAM configuration and computerised system validation approach.
Safety-first work design
LOTO, permits, safe access and GMP-controlled maintenance interventions.
Maintenance metrics
Availability, MTBF, MTTR, PM compliance, backlog and schedule adherence.
Project scope call
Clarify plant stage, project timeline, systems in scope, available documentation and decision-makers.
NDA and data-room alignment
Align drawings, equipment lists, OEM manuals, URS, commissioning plans, CMMS/EAM expectations and reliability requirements.
Detailed planning and phase gates
Define deliverables, engineering assumptions, owners, review points, acceptance criteria and the implementation sequence.
Engineer-led execution and handover
Deliver controlled asset data, maintenance logic, readiness evidence and team capability through formal review gates.
FAQ
Practical questions from pharma capital-project teams.
Clear answers on scope boundaries, timing, project inputs, handover, AI and data governance—so the right teams can define the work package before execution begins.
Scope & interfaces
Where ReliaPharma fits
Does ReliaPharma replace C&Q or validation vendors?
No. C&Q and validation demonstrate that facilities, utilities, equipment and systems meet defined requirements and intended use. ReliaPharma works alongside that stream to make the operating system ready: asset hierarchy, criticality, maintenance plans, spares, CMMS data, roles and handover controls. The interface is documented in the scope and RACI so approved evidence is reused rather than recreated.
When should the work start—and is commissioning already too late?
The best window is while requirements, vendor data and FAT/SAT plans can still be influenced—normally during design, procurement and construction. A project already in commissioning can still be supported, but the work is prioritised by critical system and Day-1 risk because the remaining choices are narrower and decisions become more time-sensitive.
Can the work be phased or contracted as standalone packages?
Yes. Scope can be separated by project phase, system, production area or deliverable package. Each package states its inputs, assumptions, owners, review gates and acceptance criteria, allowing the client to protect the critical path without entering an open-ended consulting programme.
Who needs to participate from the client team?
Typically: project engineering, maintenance and reliability, operations, Quality or CQV, the CMMS or IT/OT owner, and supply chain. They do not all need to attend every session; the RACI and review plan identify who provides input, who reviews and who accepts each deliverable.
Delivery & handover
How the work is executed and accepted
What information and system access are needed to begin?
We normally begin with the equipment or tag list, P&IDs or system drawings, URS and design documents, OEM or vendor data, the C&Q schedule, site standards and CMMS/EAM templates. Direct production-system access is not required for initial structuring; missing information is recorded in an assumptions and action log rather than silently filled in.
How do you avoid duplicating FAT, SAT or C&Q evidence?
Approved vendor and C&Q evidence is referenced and reused when it is suitable for the intended purpose. ReliaPharma does not repeat qualification testing; it connects accepted evidence to asset-data, maintenance and handover requirements, then makes gaps and unresolved interfaces visible.
What makes a deliverable ready for client handover?
A controlled deliverable identifies its source documents, assumptions, version, reviewer, owner and acceptance criteria. Drafts remain clearly separated from approved records, and the handover includes an exception log so open actions are visible rather than hidden inside a spreadsheet.
Is delivery remote, on-site or hybrid?
Most document review, data structuring and drafting can be performed remotely. Walk-downs, maintainability reviews, stakeholder workshops and final handover checks are scheduled on-site when physical verification, access or project risk makes them necessary. The delivery model is agreed in the work package.
AI, data & governance
How control is maintained
Where is AI actually used?
AI is limited to the technical workload in phases 3–5: extracting and classifying information, structuring and checking asset data, and accelerating first-pass FMEA and PM content. Governance, project requirements, commissioning acceptance, Quality approval and hypercare decisions remain human-led.
How do you use AI without creating compliance risk?
Before AI is used, the task, source set, approved environment, reviewer and acceptance criteria are defined. Outputs remain drafts until an engineer reviews and corrects them; source references, assumptions and review status are retained. The applicable assurance or validation approach is agreed with the client’s IT and Quality teams according to intended use and risk.
What happens to confidential project data?
The data-handling model is agreed before files are transferred: NDA, minimum necessary data, approved tools and storage, access rights, retention and deletion. Sensitive work can use redacted extracts or a client-controlled environment. Client information is not placed in an unapproved public AI service.
Can AI-assisted content be loaded directly into the CMMS or become a GxP record?
Not by default. AI-assisted content must pass engineering review and the client’s controlled approval process before upload or use as a GxP record. Whether a tool or workflow needs formal validation or another form of assurance depends on its intended use, risk and the client’s quality-system requirements.
Not sure where the boundary should sit?
Discuss project scope
Send the project stage, systems in scope and next major milestone. ReliaPharma can propose the smallest practical work package and show the interfaces with C&Q, Quality, project engineering and the CMMS owner.